Thursday, May 19, 2011

TroVax Studied For The Treatment Of Malignant Mesothelioma

Mesothelioma NewsTroVax studied in the treatment of mesothelioma

New York, NY - May 19, 2011

Oxford Biomedica has awarded New York-based pharmaceutical giant Pfizer non-exclusive rights to the diagnostic use of antibodies directed against the tumor antigen 5T4 and an option to sell a diagnosis based on 5T4. BioMedica and Wyeth entered into a therapeutic approach in 2001 was acquired by Pfizer in 2009. This agreement grants rights to Wyeth antibodies directed to the global market for all cancer indications 5T4.

The 5T4 antigen is the objective of Phase II BioMedica therapeutic measures against TroVax cancer vaccine, which is based on a modified vaccinia virus Ankara (MVA), which provides the 5T4 antigen. BioMedica study is to evaluate the effectiveness of TroVax in combination with docetaxel in the treatment of hormone-refractory prostate cancer (HRPC).

In addition, phase I / II study evaluated TroVax treatment with first line chemotherapy for mesothelioma is scheduled to begin in 2011, as the study of patients with ovarian cancer. Malignant mesothelioma is a rare tumor protective lining of the lungs, heart, chest and abdomen, which is almost entirely due to the long-term exposure to asbestos.

Combination therapy of mesothelioma surgery, chemotherapy and radiation, but is not healing. Mesothelioma takes on average 40 years to develop and is asymptomatic until it reaches its later stages, so it is very difficult to diagnose. Mesothelioma is most common, life expectancy is expected to be approximately six months after detection.

Although the phase III study evaluating Trist TroVax in metastatic renal cell carcinoma failed primary endpoint, the results of tests found TroVax subgroups of patients who can be of significant benefit. This led to the development of an algorithm, called the immune response against a substitute (IRS), which "gives us the opportunity to address more effectively respond to the group of patients, and we are sure that this is a novel biomarker to further substantiate the results of the current phase of development TroVax II clinical development, "said Stuart Naylor, Biomedical CSO.

Asbestosis Victim Awarded Over Asbestos Verdict In U.S. History

Thomas Brown Jr. worked in the oil fields of the Mississippi River during a period of six years during the 1970's and 80's. Meanwhile, the mixed drilling mud drilling rigs in Mississippi and offshore in the Gulf of Mexico. Brown believes it was when I was performing these duties, he was exposed to asbestos. This highly toxic mineral fiber used in a wide range of industries in the past two centuries. However, many uses of asbestos was banned in 1989 in the United States, as it became clear that the mineral was responsible for causing deadly diseases such as asbestosis, lung cancer and mesothelioma, a rare cancer of the protective membrane of the lungs, the heart, chest and abdomen.

"Brown inhalation of asbestos dust, stirring the drilling mud, which are sold by CP Chem and manufactured by Union Carbide," said Brown's lawyer. "Although asbestos has been known to cause cancers and lung diseases, continued CPR and Union Carbide Chem to market nearly 100 percent pure asbestos products long after they knew the dangers."

Following the long-term exposure of Brown, he developed asbestosis and is on oxygen 24 hours. Although both are caused by the inhalation of asbestos fibers causes mesothelioma tumor growth in the lungs, whereas asbestosis is severe scarring of lung tissue.

A jury in Raleigh, across the Mississippi with Brown and ordered Chevron Phillips Chemical and Union Carbide Corporation to allocate 322 million U.S. dollars - the biggest failure of asbestos in the United States history - for future expenses medical pain and suffering , and punitive damages.

A British Woman Is Looking For Help If You Are Exposed To Asbestos At Work

Karen Jones - formerly Karen Higginbottom - mesothelioma patients 54-years, said she received this rare form of terminal cancer caused almost exclusively by exposure to asbestos while working at Granada Theatres Frogmore, England, 1974 1981. Jones thinks she has been exposed to carcinogenic asbestos fibers during a renovation that was completed in one stage to convert the existing regime to open separate offices.

May also have been exposed to asbestos while working as a housekeeper in the city of St. Albans in 1973. asbestos that affects the protective lining of the lungs, heart, chest and abdomen, takes an average of 40 years to develop, so that the time of any of these positions must match the length of time Jones, who has exposure.

In an effort to determine the date and venue of the exhibition, the British National Asbestos Helpline (NAH) has launched an appeal on behalf of Jones for any information on the use of asbestos in a show or Granada Handley Page of the site between late 1970 and early 1980, and witnesses with knowledge of asbestos containing materials present in Saint Albans City Hospital. The NAH is particularly interested in the search for Chris Metcalfe, Janet Kahn and Pat Frazer has worked with Karen. However, information from any person, including former employees, who remember the Grand Theatre renovation, operation and maintenance of asbestos or peeling of the substances present in the pipe is also welcome.

If the suspected Jones of occupational exposure to asbestos can prove she would be able to claim a federal fund for people suffering from malignant mesothelioma.
Related Posts Plugin for WordPress, Blogger...